At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 735 enrolled
Drug / intervention
Omadacycline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
In Brief
A Phase 3 clinical trial evaluating Omadacycline and Linezolid for Bacterial Infections and Skin Structures and Soft Tissue Infections. Completed, enrolled 735 participants across 50 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedAug 2016
Primary CompletionMay 2017
Study CompletionJun 2017
TodayJul 2026
First PostedAug 24, 2016
Enrollment StartAug 1, 2016
Primary CompletionMay 26, 2017
Study CompletionJun 6, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.9 years ago
Interventions
Omadacyclinedrug
po tablets
Linezoliddrug
po tablets